Meta-analysis of non-tumour doses for radiation-induced cancer on the basis of dose-rate

HIROSHI TANOOKA

Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo, and National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan

(Received 6 July 2010; Revised 26 November 2010; Accepted 2 December 2010)

Abstract

Purpose: Quantitative analysis of cancer risk of ionising radiation as a function of dose-rate.

Materials and methods: Non-tumour dose, D_{nt}, defined as the highest dose of radiation at which no statistically significant tumour increase was observed above the control level, was analysed as a function of dose-rate of radiation.

Results: An inverse correlation was found between D_{nt} and dose-rate of the radiation. D_{nt} increased 20-fold with decreasing dose-rate from 1–10^{-8} Gy/min for whole body irradiation with low linear energy transfer (LET) radiation. Partial body radiation also showed a dose-rate dependence with a 5- to 10-fold larger D_{nt} as dose rate decreased. The dose-rate effect was also found for high LET radiation but at 10-fold lower D_{nt} levels.

Conclusions: The cancer risk of ionising radiation varies 1000-fold depending on the dose-rate of radiation and exposure conditions. This analysis explains the discrepancy of cancer risk between A-bomb survivors and radium dial painters.

Keywords: radiation cancer risk, non-tumour dose, dose-rate

Introduction

The dose-rate of ionising radiation that humans have been exposed to from natural to accidental radiation sources varies over a wide range from 10^{-9} to 10^7 Gy/min. Radiation dose-rate affects the magnitude of cancer risk even for the same total dose, and in addition changes the shape of the dose-response curve. For assessment of cancer risks of ionising radiation resulting from different exposure conditions, ideally, a set of dose response curves is needed for each dose-rate.

Currently, the estimation of human cancer risk from low doses of radiation is an important problem and data have been extensively reviewed (Committee on the Biological Effects of Ionizing Radiation [BEIR]/National Research Council [NRC], United Nations Scientific Committee on the Effects of Atomic Radiation [UNSCEAR] 1986, 2000, National Council on Radiological Protection and Measurements [NCRP] 1980, BEIR V 1990, BEIR VII 2005, National Radiological Protection Board [NRPB] 1995, Duport 2003). The dose and dose-rate effectiveness factor (DDREF) for cancer risk was determined as 2–10 depending on the target organ (NCRP 1980, International Commission on Radiological Protection [ICRP] 1991, UNSCEAR 1993, NRPB 1995). The application of the linear non-threshold (LNT) model, based on the apparently linear dose-response relation of cancer mortality obtained from extremely high dose-rate cases of A-bomb survivors, was recommended for the estimation of the cancer risk of low dose radiation for protection purposes (NCRP 2001, Brenner et al. 2003, BEIR VII 2005, ICRP 2006); however, the LNT model was questioned for its validity from experimental and epidemiological evidence (Kondo 1993, Académie des Sciences 1997, Tanooka 2001, Tubiana et al. 2006, Feinendegen et al. 2007). The history of the LNT model explains how the idea of a tolerance dose was changed to the linearity concept by incorporating the view of the geneticist (Calabrése 2009). However, a recent review of new biological and epidemiological data still adopted the LNT model (Mullenders et al. 2009). Whatever the model, there exists both linear and threshold type dose-response relations for...
radiation-induced cancers in experimental and epidemiological data. For example, the shape of the dose-response curve for cancer incidence may conform to a linear type for leukemia and solid cancers in A-bomb survivors (Chomentowski et al. 2000), while it is non-linear, or even threshold-like, for bone tumours in radium dial painters (Rowland et al. 1978) and liver tumours in thorotrast-injected patients (Anderson and Storm 1992). This discrepancy remained still to be explained.

In a previous study, non-tumour dose, \( D_{nt} \), was defined as the highest dose at which no statistically significant tumour increase was observed above the control level. It was proposed as a measure of the upper limit of radiation dose for non-detectable cancer and \( D_{nt} \) values were surveyed for in the literature. The results showed that \( D_{nt} \) depended on exposure conditions, i.e., acute, protracted, and chronic exposures for whole body and partial body radiation for either low linear energy transfer (LET) or high LET radiation, respectively, with an inverse correlation between \( D_{nt} \) and dose-rate (Tanooka 2001). The present study aimed to show the dose-rate dependence of \( D_{nt} \) more quantitatively as a function of the dose-rate of radiation.

Data base

Dose-response data covering ionising radiation exposures from non-tumour to tumour-inducing doses were surveyed in the literature and are listed in Table I. These include \( D_{nt} \) values, and corresponding dose-rates of radiation in mice, rats, dogs, and humans with different tumour types obtained under different exposure conditions. Data in the previous study (Tanooka 2001) and additional data were used for the present quantitative analysis. The data numbers in the previous study were unchanged for the convenience of comparison.

Estimation of dose-rate

The values for the dose-rate were obtained from each published paper. For external radiation, the dose-rate was clearly presented in the literature either for whole body or partial body exposures. However, for internal radiation from radioactive nuclides, the estimation of dose-rate required assumptions and calculations depending on whether internal radioactive nuclides were distributed in the whole body or deposited partially in the target organ. Moreover, the radioactivity decayed with time and the radioactive nuclide was cleared from the body. In the present analysis, an average dose-rate was estimated from the total dose divided by the exposure time or, when a decay curve was available, an average dose-rate over the 70% decay time was taken. This calculation may have resulted in a lower estimate of dose-rate and a higher estimate of \( D_{nt} \), provided that the radiation dose given only in the first half of the exposure time was effective for tumour induction. However, correction for this gave little change in the plot of \( D_{nt} \) versus dose-rate on a bi-logarithmic scale.

Results and discussion

Numerical values for \( D_{nt} \) and corresponding dose-rates obtained from various tumour systems are listed in Table I. These values were divided into four groups, i.e., whole body irradiation with low LET and high LET radiation and partial body irradiation with low LET and high LET radiation, respectively. Figure 1 shows a plot of \( D_{nt} \) against dose-rate on a bi-logarithmic scale and regression lines fitted to the data for dose-rates below 1 Gy/min. A clear dose-rate dependence of \( D_{nt} \) is seen for the four exposure patterns.

For whole body irradiation with low LET radiation, \( D_{nt} \) increased when lowering the dose-rate below 1 Gy/min and became 20-fold higher at \( 10^{-8} \) Gy/min (Figure 1a). Only one point for humans was available for the high dose-rate \( 10^7 \) Gy/min, based on the assumption that the A-bomb radiation was delivered in 1 \( \mu \)sec. It appeared that \( D_{nt} \) is constant for dose-rates between 1 and \( 10^7 \) Gy/min, as shown by the horizontal line in Figure 1a. For high LET irradiation of the whole body, there were few data available, but the dose-rate dependence of \( D_{nt} \) was seen at a level about 10- to 20-fold lower than for low LET radiation, although high LET radiation has been considered to have no dose-rate effect.

For partial body irradiation, the dose-rate dependence of \( D_{nt} \) was again seen for both low LET and high LET radiation (Figure 1b). Dose-response data for dose-rates higher than 10 Gy/min were not available in the literature. The \( D_{nt} \) level of partial body irradiation was about 5- to 10-fold higher for low LET radiations and 3- to 5-fold higher for high LET radiations than those for whole body radiation.

At an extremely high dose-rate for whole body radiation, A-bomb survivor data (Shimizu et al. 1990) gave a \( D_{nt} \) of 0.2 Gy for leukemia mortality; while mouse data from nuclear detonation experiments at similar dose-rates showed a significant increase in pituitary and Harderian gland tumours at the same dose, 0.2 Gy (Furth et al. 1954). Consequently, humans seem to be more tolerant to radiation than mice and the regression lines drawn from animal data may under-estimate \( D_{nt} \) for humans. \( D_{nt} \) values, for partial body high-LET radiation to radium dial painters (Rowland et al. 1973, 1978) and thorotrast-injected patients (Anderson and Storm 1992), were much larger than those for experimental animals (Figure 1b), again indicating a higher radiation
Table I. Dose-rate of radiation and non-tumour dose, \( D_{nt} \).

| Data number | Subject | Radiation | Tumour | Dose-rate, Gy/min | Non-tumour dose \( D_{nt} \), Gy | Reference |
|-------------|---------|-----------|--------|-------------------|-------------------------------|-----------|
| **I. Acute exposure** | | | | | | |
| 1 | Mouse RFM/Un | WB \( \gamma \)-ray | thymic lymphoma | 0.45 | 0.1 | Ullrich et al. (1976) |
| 2 | Mouse RFM/Un | WB \( \gamma \)-ray | Harderian tumour | 0.45 | 0.1 | Ullrich & Storer (1979a) |
| 3 | Mouse RFM/Un | WB \( \gamma \)-ray | uterine tumour | 0.45 | 0.25 | Ullrich & Storer (1979a) |
| 4 | Mouse RFM/Un | WB \( \gamma \)-ray | mammary tumour | 0.45 | 0.25 | Ullrich & Storer (1979a) |
| 5 | Mouse RFM/Un | WB \( \gamma \)-ray | myeloid leukemia | 0.45 | 0.25 | Ullrich & Storer (1979a) |
| 6 | Mouse RFM/Un | WB \( \gamma \)-ray | reticulum cell sarcoma | 0.45 | * > 3 | Ullrich et al. (1976), Ullrich & Storer (1979a) |
| 7 | Mouse RFM/Un | WB \( \gamma \)-ray | ovarian tumour | 0.45 | 0.1 | Ullrich et al. (1976), Ullrich & Storer (1979a) |
| 8 | Mouse RFM/Un | WB \( \gamma \)-ray | pituitary tumour | 0.45 | 0.25 | Ullrich & Storer (1979a) |
| 9 | Mouse RFM/Un | WB \( \gamma \)-ray | lung adenoma | 0.45 | 2 | Ullrich & Storer (1979a) |
| 10 | Mouse RFM/Un | WB \( \gamma \)-ray, protracted | thymic lymphoma | 0.45 | 0.1 | Ullrich & Storer (1979c) |
| 11 | Mouse RFM/Un | PB X-ray | ovarian tumour | 5.8 \( \times \) 10\(^{-5}\) | 0.5 | Ullrich & Storer (1979a) |
| 12 | Mouse RFM/Un | PB neutron | lung adenoma | 5.8 \( \times \) 10\(^{-5}\) | 0.5 | Ullrich & Storer (1979a) |
| 13 | Mouse RFM/Un | BALB/c | ovarian tumour | 5 \( \times \) 10\(^{-2}\) | 0.1 | Ullrich & Storer (1979a) |
| 14 | Mouse RFM/Un | PB X-ray | lung adenoacarcinoma | 0.4 | 0.1 | Ullrich & Storer (1979a) |
| 15 | Mouse RFM/Un | PB X-ray | ovarian tumour | 0.4 | 0.1 | Ullrich & Storer (1979a) |
| 16 | Mouse RFM/Un | PB fission neutron | ovarian tumour | 5 \( \times \) 10\(^{-2}\) | 0.25 | Ullrich & Storer (1979a) |
| 17 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 18 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 19 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 20 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 21 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 22 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 23 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 24 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 25 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 26 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 27 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 28 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 29 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 30 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 31 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 32 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 33 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 34 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |
| 35 | Mouse RFM/Un | PB \( \gamma \)-ray | thymic lymphoma | 5 \( \times \) 10\(^{-2}\) | 0.025 | Ullrich & Storer (1979a) |

II. Chronic exposure

1) Internal radiation

| Data number | Subject | Radiation | Tumour | Dose-rate, Gy/min | Non-tumour dose \( D_{nt} \), Gy | Reference |
|-------------|---------|-----------|--------|-------------------|-------------------------------|-----------|
| 31 | Mouse C57BL| PB \( ^{60} \)Sr \( \beta \)-ray, injected | bone sarcoma | 2 \( \times \) 10\(^{-5}\) | 0.2 | Finkel et al. (1959) |
| 32 | Mouse C57BL| PB \( ^{90} \)Y \( \beta \)-ray, oral | thymic lymphoma | 6.4 \( \times \) 10\(^{-7}\) | 0.71 | Yamamoto et al. (1998) |
| 33 | Mouse C57BL| PB \( ^{85} \)Sr \( \beta \)-ray, oral | thymic lymphoma | 1.7 \( \times \) 10\(^{-4}\) | 3.3 | Lee et al. (1982) |
| 34 | Mouse C57BL| PB \( ^{213} \)Po \( \beta \)-ray, injected | thymic lymphoma | 7 \( \times \) 10\(^{-4}\) | 1 | Dudoignon et al. (1999) |
| 35 | Mouse C57BL| PB \( ^{222} \)Rn \( \alpha \)-ray, inhaled | thymic lymphoma | 3 \( \times \) 10\(^{-5}\) | 0.19 | Medier et al. (1994) |

(continued)
| Data number | Subject          | Radiation$^a$                        | Tumour            | Dose-rate, Gy/min | Non-tumour dose $D_{0.0}$ Gy | Reference                                      |
|-------------|------------------|-------------------------------------|-------------------|-------------------|-------------------------------|-----------------------------------------------|
| 36          | " Wister        | PB $^{239}$PuO$_2$ $\gamma$-ray, inhaled | "                 | $2.5 \times 10^{-4}$ | 0.25                          | Sanders et al. (1977)                        |
| 37          | " "             | PB $^{239}$PuO$_2$ $\gamma$-ray, inhaled | "                 | $3.4 \times 10^{-7}$ | 0.05                          | "                                             |
| 38          | " "             | PB $^{244}$CmO$_2$ $\gamma$-ray, inhaled | "                 | $1.9 \times 10^{-5}$ | 0.18                          | Sanders & Mahaffey (1978)                     |
| 39          | " Dog beagle    | PB $^{90}$Sr $\beta$-ray, injected   | bone sarcoma      | $6 \times 10^{-3}$  | 30                            | Mays & Finkel (1980)                         |
| 40          | " "             | PB $^{144}$Sr $\beta$-ray, inhaled   | lung tumour       | $3.2 \times 10^{-3}$  | 6.7                           | White et al. (1993)                          |
| 41          | " "             | PB $^{226}$Ra $\gamma$-ray, injected | bone sarcoma      | $1.3 \times 10^{-5}$  | 5                             | White et al. (1994)                          |
| 42          | " "             | PB $^{226}$Ra $\gamma$-ray, injected | bone sarcoma      | $5 \times 10^{-7}$   | 0.9                           | "                                             |
| 43          | " "             | PB $^{226}$Ra $\beta$-ray, injected  | "                 | $7 \times 10^{-7}$   | 2                             | Rowland et al. (1973)                        |
| 44          | " "             | PB $^{228}$Ra $\beta$-ray, injected  | liver cancer      | $2.8 \times 10^{-7}$  | 5                             | "                                             |
| 45          | " Human thorotrast patient | PB $^{232}$ThO$_2$ $\gamma$-ray, injected | liver cancer      | $1.1 \times 10^{-7}$  | *2                            | Anderson & Storr (1992)                       |
| 46          | " dial painter  | PB $^{226}$Ra + $^{228}$Ra $\alpha + \beta$, oral | bone sarcoma      | $4.9 \times 10^{-7}$  | *10                           | Rowland et al. (1978)                        |
| 47          | " Mouse RFM/Un male | WB $\gamma$-ray | myeloid leukemia | $3 \times 10^{-5}$  | 1.5                           | Upton et al. (1970)                          |
| 48          | " RFM/Un female | "                                   | "                 | $5 \times 10^{-6}$   | 2.5                           | "                                             |
| 49          | " CBA/H        | PB $^{204}$TI $\beta$-ray, skin     | skin tumour       | $2 \times 10^{-2}$    | 16                            | Hulse et al. (1983)                          |
| 50          | " ICR          | PB $^{90}$Sr-$^{90}$Y $\beta$-ray, skin | "                 | 1.5 Gy/week, 6 months | *40                           | Ootsuyama & Tanooka (1991, 1993)             |
| 51          | " Dog beagle   | WB $\gamma$-ray, continuous myeloproliferative disease | "                 | $2 \times 10^{-6}$    | 8.6                           | Thompson (1989)                              |
| 52          | " Human high radiation background area in India | "                      | "                 | $1.3 \times 10^{-8}$  | *no cancer increase | Nair et al. (1999)                           |
| 53          | " high radiation background area in China | "                      | "                 | $5.7 \times 10^{-9}$  | *no cancer increase | Chen & Wei (1990)                            |
| Data added  | " Dog beagle   | PB $^{226}$Ra $\gamma$-ray | bone sarcoma      | $7 \times 10^{-7}$  | 0.44                          | Raabe (1984)                                 |
| 55          | " Mouse C.B-17 | WB $\gamma$-ray | thymic lymphoma | $5 \times 10^{-1}$  | 1                             | Ishii-Ohba et al. (2007)                     |
| 56          | " C57BL/6j     | "                                   | "                 | $2 \times 10^{-5}$  | *$>7$                         | Ins et al. (2005)                            |

$^a$WB: Whole body radiation. PB: Partial body radiation.

*Not included in calculation for the regression line.
tolerance of humans. The other extreme case is the absence of thymic lymphoma induction in mice irradiated at $2 \times 10^{-5}$ mGy/min with a total whole body dose of 7.2 Gy; whereas, acute radiation given in four fractions with the same total dose yielded a 90% tumour incidence (Ina et al. 2005), as was originally found in the early experiments of Kaplan and Brown (1952).

Fractionation of radiation dose at a fixed dose-rate within a defined time interval lowers cancer incidence, as shown in the induction of skin tumours by local irradiation in rats (Burns et al. 1973, 1975, 1993). However, fractionation necessarily involves repetitive irradiations, which results in a tumour-enhancing effect as seen for mouse thymic lymphoma induction (Kaplan and Brown 1952) and also in mouse skin tumour induction (Ootsuyama and Tanooka 1991). It should be noted that the repetitive treatment is efficient for chemical induction of tumours. This contradictory effect should be considered in analysing the dose-rate effect.

Figure 2 summarises the regression lines for the four exposure patterns. These four lines are thought to cover all possible radiation exposure cases and hopefully to serve as a measure of cancer risk for any exposure situation in the human environment. Total whole body radiation doses received over 70 years from the natural environment high background radiation areas in Kerala, India (Nair et al. 1999) and Yanjiang, China (Chen and Wei 1991) are much smaller than $D_{nt}$ for the respective dose-rates in each district (Figure 2). The radiation dose to astronauts in space (Horneck et al. 2003) is also shown in Figure 2, indicating a value close to $D_{nt}$ even with a radiation shield. The cancer risk of medical examination with computer tomography (CT) has been analysed on the basis of whole-body data of A-bomb survivors (Berrington de Gonzalez and Darby 2004); however, this risk should have been analysed on the basis of partial body data. The highest possible dose for CT was still far lower than the corresponding $D_{nt}$. Recently, Tubiana et al. (in press) reported the dose response of second cancer incidence after radiation therapy with a $D_{nt}$ of about 1 Gy based on a large number of patients. This study provides important data on human exposure to partial body low LET radiation.

There are differences in the radiation sensitivity of tumour induction, depending on the type of tumour and host sensitivity. $D_{nt}$ is much smaller in repair-deficient mice compared to wild-type mice (Ishii-Ohba et al. 2007), indicating that the regression lines represent the wild-type character of the hosts. Currently, a large scale life-time exposure of mice to external $\gamma$ rays with graded dose-rates from 1–800 mGy per 22 h a day (dose-rate: $7.5 \times 10^{-6} – 6 \times 10^{-3}$ Gy/min, total dose for 3 years: 1.1 – 876 Gy) together with control mice is being conducted and chromosome aberration data have been reported (Tanaka et al. 2009). Such experiments will give more accurate data for the effect of dose-rate on tumour induction. Further data will be needed to cover the whole dose-rate range for tumour induction.
Summary

Meta-analysis of the non-tumour dose, \( D_{\text{nt}} \), of ionising radiation showed a clear dependence on dose-rate over a wide range for four exposure conditions, i.e., whole body irradiation with low LET or high LET radiation and partial body irradiation with low LET or high LET radiation. From the regression lines for the relation between dose-rate and \( D_{\text{nt}} \), a cancer risk or tolerance level of radiation could be estimated for a variety of exposure conditions. An apparent discrepancy in radiation-induced tumour data could be explained in terms of dose-rate.

Acknowledgements

I thank Dr Kouichi Tatsumi, Radiation Effects Association, Dr Toshihiko Sado, National Institute of Radiological Sciences, and Dr Tomotaka Sobue, National Cancer Center, for useful discussions and suggestions, Dr Takahiro Ochiya, National Cancer Center, for support of this work, Dr Gerda Horneck, Institute of Aerospace Medicine, German Aerospace Center, Germany, for information on the radiation dose in space, Dr Bruce B. Boecker, Loveless Respiratory Research Institute, USA, for information on internal emitters, and Dr Maurice Tubiana, University of Paris, France, for providing me with valuable data prior to publishing.

Declaration of interest: The author reports no conflicts of interest. The author alone is responsible for the content and writing of the paper.

References

Académie des Sciences, France. 1997. Problems associated with the effects of low doses of ionizing radiations. Report 38. Amsterdam: Elsevier.

Albert RE, Burns FJ, Bennet P. 1972. Radiation-induced hair-follicle damage and tumour formation in mouse and rat skin. Journal of National Cancer Institute 49:1131–1137.

Anderson M, Storm HH. 1992. Cancer incidence among Danish thorotrast-exposed patients. Journal of National Cancer Institute 84:1131–1137.

Bartsra RW, Bentvelzen PAJ, Zoetelief J, Mulder AH, Broeze JJ, van Bekkum DW. 2000. The effects of fractionated gamma radiation on induction of mammary carcinoma in normal and estrogen-treated rats. Radiation Research 153:557–569.

Berrington de Gonzalez A, Darby S. 2004. Risk of cancer from diagnostic X-rays: Estimates for the UK and 14 other countries. The Lancet 363:345–351.

Brenner DJ, Doll R, Goodhead DT, Hall EH, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, Ron E, Sachs RK, Samet JM, Setlow RB, Zaider M. 2003. Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know. Proceedings of National Academy of Sciences of the USA 100:13761–13766.
Non-tumour dose and dose-rate

Hulse EV, Mole RH. 1969. Skin tumour incidence in CBA mice given fractionated exposures to low energy beta particles. British Journal of Cancer 23:452–463.

Ina Y, Tanooka H, Yamada T, Sakai K. 2005. Suppression of thymic lymphoma induction by life-long low dose-rate irradiation accompanied by immune activation in C57Bl/6 mice. Radiation Research 163:153–158.

International Commission on Radiological Protection (ICRP). 1991. Publication 60: 1990. Recommendations of the international commission on radiological protection. Oxford: Pergamon.

International Commission on Radiological Protection (ICRP). 2006. Publication 99: Low-dose extrapolation of radiation related cancer risk. Oxford: Elsevier.

Ishii-Ohiba H, Kobayashi S, Nishimura M, Shimada Y, Tsuji H, Sado T, Ogisu T. 2007. Existence of a threshold-like dose for γ-ray induction of thymic lymphomas and no susceptibility to radiation-induced solid tumours in SCID mice. Mutation Research 619:124–133.

Kaplan HS, Brown MB. 1952. A quantitative dose-response study of lymphoid-tumour development in irradiated C57 black mice. Journal of National Cancer Institute 13:185–208.

Kondo S. 1993. Health effects of low-level radiation. Osaka: Kinki University Press and Madison: Medical Physics Publishing.

Lee W, Chiaccierrini RP, Shelein B, Telles NC. 1982. Thyroid tumours following 131I or localized X irradiation to the thyroid and pituitary glands in rats. Radiation Research 92:307–319.

Maisin JR, Wambersie GB, Gerber GB, Mattelin G, Lambi- Collier M, Gueulette J. 1983. The effects of a fractionated gamma irradiation on life shortening and disease incidence in BALB/c mice. Radiation Research 94:359–373.

Mays CW, Finkel MP. 1980. RBE of α-particles vs. β-particles in bone sarcoma induction. In: Radiation Protection: A systematic approach to safety. Proc. 5th Congress of International Radiation Protection Association. Oxford: Pergamon Press. pp 661–665.

Morlier JP, Morin M, Monchaux G, Fritsch P, Pineau JF, Chameaud J, Lafuma J, Masse R. 1994. Lung cancer incidence after exposure of rats to low doses of radon: Influence of dose-rate. Radiation Protection and Dosimetry 56:93–97.

Mullenders L, Atkinson M, Paretzke H, Sabatier L, Bouffler S. 2009. Assessing cancer risks of low-dose radiation. Nature Reviews Cancer 9:596–604.

Nair MK, Nambi KSV, Amma NS, Gangadharan P, Jayakrishnam P, Jayadevan S, Cherian V, Raghuram KN. 1999. Population study in the high natural background radiation area in Kerala, India. Radiation Research 152:S145–148.

National Council on Radiological Protection and Measurements (NCRP). 1980. Report 64: Influence of dose and its distribution in time on dose-response relationships for low LET radiations. Bethesda, MD: National Council on Radiological Protection and Measurements.

National Council on Radiological Protection and Measurements (NCRP). 2001. Report 136: Evaluation of the linear non-threshold dose-response model for ionizing radiation. Bethesda, MD: National Council on Radiological Protection and Measurements.

National Radiological Protection Board (NRPB). UK. 1995. Risk of radiation-induced cancer at low doses and low dose rates for radiation protection purposes. Report. Vol. 6, No. 1.

Ootsuyama A, Tanooka H. 1991. Threshold-like dose of local β-irradiation repeated throughout the life span of mice for induction of skin and bone tumours. Radiation Research 125:98–101.

Ootsuyama A, Tanooka H. 1993. Zero tumour incidence in mice after repeated lifetime exposures to 0.5 Gy of beta radiation. Radiation Research 134:244–246.

Raabe OG. 1984. Comparison of the carcinogenicity of radium and bone-seeking actinides. Health Physics 46:1241–1258.
Rowland RE, Keane AT, Lucas HF. 1973. A preliminary comparison of the carcinogenicity of 226Ra and 228Ra in man. In: Sanders CL, Busch RH, Ballou JE, Mahlum DD, editors. Radionuclide carcinogenesis. Springfield: US Department of Commerce. pp 406–420.

Rowland RE, Stehney AF, Lucas HF. 1978. Dose-response relationships for female radium dial workers. Radiation Research 76:368–383.

Sanders CL, Dagle GE, Cannon WC, Powers GJ, Meier DM. 1977. Inhalation carcinogenesis of high-fired 238PuO2 in rats. Radiation Research 71:528–546.

Shimizu Y, Kato H, Schull WJ. 1990. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950–1985: Part 2: Cancer mortality based on the recently revised doses (DS86). Radiation Research 121:120–141.

Tanaka K, Kohda A, Satoh K, Toyokawa T, Ichinoe K, Ohtaki M, Oghiso Y. 2009. Dose-rate effectiveness for unstable-type chromosome aberrations detected in mice after continuous irradiation with low-dose-rate γ-rays. Radiation Research 171:290–301.

Tanooka H. 2001. Threshold dose-response in radiation carcinogenesis: An approach from chronic β-irradiation experiments and a review of non-tumour doses. International Journal of Radiation Biology 77:541–551.

Thompson RC. 1989. Life-span effects of ionizing radiation in the beagle dog. A summary account of four decades of research funded by the US Department of Energy and its predecessor agencies. Pacific Northwest Laboratory Report PNL-6822 UC-408. pp 1–323.

Tubiana M, Aurengo A, Averbeck D, Massé R. 2006. Recent reports on the effect of low doses of ionizing radiation and its dose-effect relationship. Radiation and Environmental Biophysics 44:245–251.

Tubiana M, Diallo I, Chavaudra J, Lefkopoulos D, Bourhis J, Girinsky T, Brider A, Hawkins M, Haddy N, El-Fayech C, Adjadi E, Glero E, de Vathaire F. 2010. A new method of assessing the dose-carcinogenic effect relationship in patients exposed to ionizing radiation. A concise presentation of preliminary data. Health Physics, in press.

Ullrich RL, Jernigan MC, Cosgrove GE, Satterfield LC, Bowles ND, Storer JB. 1976. The influence of dose and dose-rate on the incidence of neoplastic disease in RFM mice after neutron irradiation. Radiation Research 68:115–131.

Ullrich RL, Storer JB. 1979a. Influence of γ-irradiation on the development of neoplastic disease in mice. I. Reticular tissue tumours. Radiation Research 80:303–316.

Ullrich RL, Storer JB. 1979b. Influence of γ-irradiation on the development of neoplastic disease in mice. II. Solid tumours. Radiation Research 80:317–324.

Ullrich RL, Storer JB. 1979c. Influence of γ-irradiation on the development of neoplastic disease in mice. III. Dose-rate effects. Radiation Research 80:325–342.

United Nations Scientific Committee on the Effects of Atomic Radiation (UNCEAR). 1986. Dose-response relationships for radiation-induced cancer. In: Sources and effects of ionizing radiation: Genetic and somatic effects of ionizing radiation. Report to the General Assembly. New York: United Nations.

United Nations Scientific Committee on the Effects of Atomic Radiation (UNCEAR). 1993. Influence of dose and dose-rate on stochastic effects of radiation. In: Sources and effects of ionizing radiation. Report to the General Assembly, Annex F. New York: United Nations.

United Nations Scientific Committee on the Effects of Atomic Radiation (UNCEAR). 2000. Biological effects at low radiation doses: Models, mechanisms and uncertainties. In: Sources and effects of ionizing radiation: genetic and somatic effects of ionizing radiation. Report to the General Assembly, Annex I. New York: United Nations.

Upton AC, Randolph ML, Conklin JW. 1970. Late effects of fast neutrons and gamma-rays in mice as influenced by the dose-rate of irradiation: Induction of neoplasia. Radiation Research 41:467–491.

White RG, Raabe OG, Culbertson MR, Parks NJ, Samuels SJ, Rosenblatt LS. 1993. Bone sarcoma characteristics and distribution in beagles fed strontium-90. Radiation Research 136:178–189.

White RG, Raabe OG, Culbertson MR, Parks NJ, Samuels SJ, Rosenblatt LS. 1994. Bone sarcoma characteristics and distribution in beagles injected with radium-226. Radiation Research 137:361–370.

Yamamoto O, Seyama T, Itoh H, Fujimoto N. 1998. Oral administration of tritiated water (HTO) in mouse. III. Low dose-rate irradiation and threshold dose-rate for radiation risk. International Journal of Radiation Biology 73:535–541.